US EditionPublished • loading... • Updated
BPIQ Model Portfolios Continue to Crush Biotech Benchmarks
Summary by BiopharmIQ by Amp
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
BPIQ Model Portfolios Continue to Crush Biotech Benchmarks
SummarySince 2023, BPIQ model portfolios built around biopharma hedge-fund consensus holdings have consistently outperformed the biotech benchmarks XBI and IBB.Background (one paragraph, no fluff)We launched our first consensus-based portfolio (Top 20s) on 4/1/2023 and, by 9/30/2023, applied the hedge-fund favorites framework across the rest of the lineup (Top 50, Top 15, Run-Up, and Top 10 as well). Top 10 received further refinements at the en…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
